Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Yusri Elsayed"'
Autor:
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi W. Hilder, Jeffery Russell, Jeffrey Infante, Yusri Elsayed, Jennifer Smit, Jenna D. Goldberg
Publikováno v:
Blood Advances. 7:644-648
B-cell maturation antigen (BCMA) is selectively expressed as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of patients with MM. The bispecific antibodies
Autor:
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W. Hilder, Qun Jiao, Brett Hanna, Homer C Adams, Yu-Nien Sun, Amarnath Sharma, Jennifer Smit, Jeffrey R. Infante, Jenna D. Goldberg, Yusri Elsayed
Publikováno v:
Targeted Oncology. 17:433-439
Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evalua
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Legend - PDF file 66K, Supplementary legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bd9512e90e8428b684e29321f17aee
https://doi.org/10.1158/1078-0432.22449674
https://doi.org/10.1158/1078-0432.22449674
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).Experimental Design: In this first-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c32c02ec5d8571cf1af10f27c04572d3
https://doi.org/10.1158/1078-0432.c.6521723
https://doi.org/10.1158/1078-0432.c.6521723
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Table 2 - PDF file 58K, A summary of PK parameters of quisinostat estimated on day 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5abd1da2e5d291dae19258963466470c
https://doi.org/10.1158/1078-0432.22449668.v1
https://doi.org/10.1158/1078-0432.22449668.v1
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Figure 1a,b - PDF file 45K, Plasma concentration-time profile of 12 mg quisinostat on (a) day 1 and (b) at steady state for MWF treatment schedule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e0706cd6567a0bafdcd4d473361bc5f
https://doi.org/10.1158/1078-0432.22449677
https://doi.org/10.1158/1078-0432.22449677
Autor:
Udai Banerji, Johann S. de Bono, T.R. Jeffry Evans, John Camm, Charles Phelps, Ann Forslund, Johan W. Smit, Steve Mcclue, Yusri Elsayed, Peter Hellemans, Nele Fourneau, Adam Stewart, Richard Cowan, Ruth Plummer, Rebecca S. Kristeleit, Richard Baird, Balaji Venugopal
Supplementary Table 1 - PDF file 54K, Number (percentage) of patients exhibiting increased ventricular ectopic activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc3771585f876d8b010770be7fcfcb2
https://doi.org/10.1158/1078-0432.22449671
https://doi.org/10.1158/1078-0432.22449671
Autor:
Maria-Victoria Mateos, Jenna D. Goldberg, Ajai Chari, Arnob Banerjee, Lotfi Benboubker, Raluca Verona, Jeffrey R. Infante, Tara Stephenson, Jesús F. San-Miguel, Alfred L. Garfall, Yusri Elsayed, Manisha Bhutani, Hareth Nahi, Lionel Karlin, Niels W.C.J. van de Donk, Suzette Girgis, Saad Z. Usmani, Lixia Pei, Laura Rosiñol, Albert Oriol, Amrita Krishnan
Publikováno v:
The Lancet, 398(10301), 665-674. Elsevier Limited
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Usmani, S Z, Garfall, A L, van de Donk, N W C J, Nahi, H, San-Miguel, J F, Oriol, A, Rosinol, L, Chari, A, Bhutani, M, Karlin, L, Benboubker, L, Pei, L, Verona, R, Girgis, S, Stephenson, T, Elsayed, Y, Infante, J, Goldberg, J D, Banerjee, A, Mateos, M-V & Krishnan, A 2021, ' Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study ', The Lancet, vol. 398, no. 10301, pp. 665-674 . https://doi.org/10.1016/S0140-6736(21)01338-6
LANCET
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myelo
Autor:
Min Chul Kwon, Olivier Querolle, Xuedong Dai, Jan Willem Thuring, Tinne Verhulst, Ann Marien, Dries Goffin, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Karin Verstraeten, Sara El Ashkar, Shanna M Hogeling, Frank Jacob, Petra Vinken, Nicolas Darville, Vineet Pande, Daniel Krosky, Gregor Urbanietz, Bie Verbist, Lucille A. Ferrante, Christina Diane Drenberg, David Wilson, Ricardo M. Attar, Jan Jacob Schuringa, Nikki Daskalakis, Kathryn Packman, Christine Pietsch, Yusri Elsayed, Ulrike Philippar
Publikováno v:
Blood. 140:5928-5929
Autor:
Nate Majewski, Leopoldo Luistro, Gordon Powers, Rupesh Nanjunda, Diana Chin, Ricardo Attar, Francois Gaudet, Yingzhe Li, Kodandaram Pillarisetti, Xiaochun Zhang, Yusri Elsayed, Mark Mendonca, Packman Kathryn E, Alexander Babich, Baldwin Eric Thomas
Publikováno v:
Blood Adv
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells. BCMA is highly expressed on plasmablasts and plasma cells from multiple myelo